CSP
9 min read
30

Lucara Announces Operating Guidance For 2025

December 3, 2024
0

Reading Time: 6 minutes VANCOUVER, B.C., Dec. 3, 2024 /CNW/ – (LUC – TSX, LUC – BSE, LUC – Nasdaq Stockholm) Lucara Diamond Corp. (“Lucara” or the “Company”) is pleased to provide operating guidance for 2025. All amounts are in USD unless otherwise stated. William

Continue Reading
CSP
5 min read
14

Correction: Form 8.3 – Direct Line Insurance Group Plc

December 3, 2024
0

Reading Time: 4 minutes PLEASE SEE AMENDED CLASS OF RELEVANT SECURITY     FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION  

Continue Reading
CSP
1 min read
25

Nordea Bank Abp: Repurchase of own shares on 03.12.2024

December 3, 2024
0

Reading Time: < 1 minute Nordea Bank AbpStock exchange release – Changes in company’s own shares03.12.2024 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 03.12.2024 completed repurchases of own shares (ISIN: FI4000297767) as follows: Trading venue (MIC Code) Number of shares Weighted average

Continue Reading
CSP
5 min read
29

Biosergen AB receives approximately SEK 44.9 million through warrants of series TO3

December 3, 2024
0

Reading Time: 4 minutes Biosergen AB (”Biosergen” or the “Company”) announces today the outcome of the exercise of warrants of series TO3, which were issued in connection with a rights issue in the Company during the first quarter 2024. In total, 91,701,328 warrants of series TO3

Continue Reading
CSP
6 min read
11

Biosergen AB conducts a directed share issue to underwriters in connection with the completed exercise period for warrants of series TO3

December 3, 2024
0

Reading Time: 4 minutes The exercise period for Biosergen AB (”Biosergen” or the “Company”) warrants of series TO3 (the “Warrants”) was completed on November 29, 2024. In accordance with the underwriting agreements entered into in connection with the exercise of the Warrants, the Board of Directors

Continue Reading
CSP
1 min read
8

#24-415 Listing of Derivatives at NGM

December 3, 2024
0

Reading Time: < 1 minute Information about various derivatives that will be listed at NGM. For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market

Continue Reading
CSP
1 min read
7

#24-416 Delisting of Derivatives from NGM

December 3, 2024
0

Reading Time: < 1 minute Information about certain derivatives that will be delisted from NGM. For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market

Continue Reading
CSP
5 min read
7

Correction: Warrants of series TO5 were subscribed to approximately 87.1 percent and Wyld Networks AB receives approximately SEK 234 thousand

December 3, 2024
0

Reading Time: 4 minutes NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF

Continue Reading
CSP
1 min read
7

Fondia Plc: Share repurchase 3.12.2024

December 3, 2024
0

Reading Time: < 1 minute Fondia Plc Company release 3.12.2024 at 6.45 p.m. EET   Fondia – Acquisition of own shares 3.12.2024   Fondia Plc   First North Finland   Date 3.12.2024 Exchange transactions Buy Share class FONDIA Amount, shares 841 Average price/share, EUR 5,05

Continue Reading
Annual Report 2023/2024 – Diamyd Medical AB
CSP
1 min read
10

Annual Report 2023/2024 – Diamyd Medical AB

December 3, 2024
0

Reading Time: < 1 minute Diamyd Medical’s Annual Report for the financial year 2023/2024 is now available in English. The Annual Report is attached as a PDF and is available at www.diamyd.com. For further information, please contactUlf Hannelius, CEO, phone +46

Continue Reading